Modern management of abnormal uterine bleeding: the levonorgestrel intra-uterine system.
Since its launch, more than 9 million women worldwide have used the levonorgestrel intra-uterine system (IUS) for contraception, as a treatment for heavy menstrual bleeding and as the progestogen component of hormone-replacement therapy. For women in their reproductive years, the IUS has become one of the most acceptable medical treatments for menorrhagia, reducing referrals to specialists and decreasing the need for operative gynaecological surgery. This article will outline the development of the IUS, highlighting the most important recent areas of research covering its use to control menstrual blood loss and pain.
Mansour
Diana
D
Graingerville Clinic, Newcastle General Hospital, Newcastle upon Tyne, UK. diana.mansour@newcastle-pct.nhs.uk
D003271:Contraceptive Agents, Female / Q000008:administration & dosage* / Q000493:pharmacokinetics; D003362:Cost-Benefit Analysis; D004714:Endometrial Hyperplasia / Q000188:drug therapy; D004715:Endometriosis / Q000188:drug therapy; D005260:Female; D006801:Humans; D007436:Intrauterine Devices, Medicated; D016912:Levonorgestrel / Q000008:administration & dosage* / Q000493:pharmacokinetics; D008595:Menorrhagia / Q000517:prevention & control*
D003271:Contraceptive Agents, Female; D016912:Levonorgestrel